Letter to the EditorPeripubertal treatment with cannabidiol prevents the emergence of psychosis in an animal model of schizophrenia
Section snippets
Contributors
Fernanda F. Peres, Rodrigo A. Bressan, Antonio W. Zuardi, Jaime E. C. Hallak, José A. Crippa and Vanessa C. Abilio designed the study. Authors Fernanda F. Peres, Mariana C. Diana, Mayra A. Suiama, Verônica Justi and Valéria Almeida conducted the experiments, statistical analysis and managed the literature search. Authors Fernanda F. Peres and Vanessa C. Abilio wrote the first draft of the manuscript. All authors contributed to and have approved the final manuscript.
Conflict of interest
J.E.H., A.W.Z. and J.A.C. are co-inventors of the patent “Fluorinated CBD compounds, compositions and uses thereof. Pub. No.: WO/2014/108899. International Application No.: PCT/IL2014/050023”.
References (8)
- et al.
Cannabidiol exhibits anxiolytic but not antipsychotic property evaluated in the social interaction test
Prog. Neuro-Psychopharmacol. Biol. Psychiatry
(2013) - et al.
Effects of antipsychotics and amphetamine on social behaviors in spontaneously hypertensive rats
Behav. Brain Res.
(2011) - et al.
A review of 25 years of the social interaction test
Eur. J. Pharmacol.
(2003) - et al.
To model a psychiatric disorder in animals: schizophrenia as a reality test
Neuropsychopharmacology
(2000)
Cited by (22)
Toll-like receptor signalling as a cannabinoid target
2024, Biochemical PharmacologyPhytocannabinoids and schizophrenia: Focus on adolescence as a critical window of enhanced vulnerability and opportunity for treatment
2021, Pharmacological ResearchCitation Excerpt :Therefore, these studies suggest that independently of the experimental model, CBD can reverse the object recognition memory dysfunction, but not the impairment of social recognition memory. Similarly for the social deficits, adolescent/peripubertal CBD treatment counteracted the development of cognitive deficits in different neurodevelopmental models such as the Poly I:C [164], the MAM [165], the THC [166] and the SHR model [156]. Overall these data suggest that CBD effects on cognitive-like symptoms may involve a broad of different aspects from non-emotional related behaviours to short-/long-term or aversive memories (Table 3).
Adolescent cannabinoid exposure interacts with other risk factors in schizophrenia: A review of the evidence from animal models
2020, Neuroscience and Biobehavioral ReviewsCitation Excerpt :However, the variability in protective effects of CBD, much like the adverse effects of THC, could be largely due to dose differences. For example, social deficits induced by either ACE or other risk factors were not remedied by low dose CBD exposure as shown by multiple studies (Peres et al., 2018; Murphy et al., 2017; Peres et al., 2016), however are reversed by high dose CBD treatment (Osborne et al., 2017). Similarly, one study found no protective effect of adolescent CBD on schizophrenia-like behavioural changes in adulthood (Kasten et al., 2019).
Altered dopamine D3 receptor gene expression in MAM model of schizophrenia is reversed by peripubertal cannabidiol treatment
2020, Biochemical PharmacologyCitation Excerpt :Among new candidate compounds, accumulating evidence points towards cannabidiol (CBD), the most abundant non-euphoric phytocannabinoid, endowed with a favourable pharmacological profile, as an alternative treatment option for those SCZ symptoms that are not satisfactorily ameliorated by current theraphies [8,9]. In agreement with the hypothesis that early intervention at a critical period (the so-called window of opportunity) may be effective in circumventing the transition to SCZ [10], it has been observed that peripubertal CBD treatment prevents the development of SCZ-like alterations in animal models at adulthood [11,12]. In particular, CBD regulates the mesolimbic DAergic system, which may, at least in part, underlie its behavioral effects [13].